Medication-Induced Psychosis Management

Evaluating Medications

Trazodone can cause hallucinations in dementia patients, primarily documented in elderly populations with cognitive impairment, not young adults, according to the American Academy of Family Physicians 1
Oxcarbazepine is generally well-tolerated for seizure control with minimal psychiatric side effects at 300mg BID, as reported in Translational Neurodegeneration 3
Trazodone is not recommended for acute hallucination management due to its delayed onset, as stated by the Praxis Medical Insights 2

Quetiapine 25mg orally is recommended for acute symptom control, providing effective management of hallucinations with lower risk of extrapyramidal symptoms, as suggested by the Praxis Medical Insights 4
Quetiapine dosing starts at 25mg orally, which can be repeated every 12 hours if needed, with advantages including sedating properties, minimal EPS risk, and no prolactin elevation, according to the Praxis Medical Insights 4
Monitoring for quetiapine includes checking blood pressure for orthostatic hypotension after the first dose, as recommended by the Praxis Medical Insights 4

Visual hallucinations may indicate Charles Bonnet syndrome if any degree of vision loss exists, as reported in Ophthalmology 5, 6

Olanzapine 2.5mg daily is a well-tolerated alternative with good efficacy for hallucinations, as stated in the Annals of Oncology and American family physician 1, 7
Risperidone 0.25mg daily is effective but has a higher EPS risk than quetiapine, according to the American family physician 1
Aripiprazole is a lower sedation option that is effective for psychotic symptoms, as reported in the Annals of Oncology 7